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Abstract: The diagnosis of hypersensitivity pneumonitis (HP) relies on the clinical evaluation
of a number of features, including a history of significant exposure to potentially causative
antigens, physical examination, chest CT scan appearances, bronchoalveolar lavage lymphocytosis,
and, in selected cases, histology. The presence of fibrosis is associated with higher morbidity and
mortality. Differentiating fibrotic HP from the idiopathic interstitial pneumonias can be a challenge.
Furthermore, even in the context of a clear diagnosis of fibrotic HP, the disease behaviour can parallel
that of idiopathic pulmonary fibrosis in a subgroup, with inexorable progression despite treatment.
We review the current knowledge on the diagnosis, management, and prognosis of HP with particular
focus on the fibrotic phenotype.
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1. Introduction
Hypersensitivity pneumonitis (HP), also known as extrinsic allergic alveolitis, is a clinical
syndrome characterized by variable presentations (acute, subacute, and chronic/fibrotic). Frequently,
an overlap of the different disease forms is observed in daily clinical practice. An exaggerated
immune response to repeated inhalation of environmental antigens is the proposed pathogenetic
mechanism [1]. As only a small proportion of individuals exposed to specific antigens develop the
disease, and contributing factors of a predisposed genetic background are likely to be implicated.
Critical immunopathological changes occur in the lung microenvironment. In fibrotic HP, ongoing
immune activation and inflammation are believed to lead to the expansion/activation of the fibroblast
population and the accumulation of extracellular matrix [2,3]. The reasons why only some individuals
develop progressive fibrosis in HP are not known. Although our knowledge of the pathogenesis and
the list of environmental antigens associated with HP has continued to increase, the clinical definition
of the disease remains elusive. Two major attempts to reach an agreement on a definition by groups of
international experts failed to provide a widely accepted and validated diagnostic approach [1,4].
In this context, symptoms, radiographic and histopathological findings in patients with fibrotic
HP often overlap with those described in patients with idiopathic interstitial pneumonias (IIPs), as HP
findings of bronchiolocentric granulomatous inflammation are often associated with a background
pattern of usual interstitial pneumonia (UIP) or non-specific interstitial pneumonia (NSIP) [5,6]. Indeed,
the updated diagnostic guidelines for idiopathic pulmonary fibrosis (IPF) recommend the exclusion of
fibrotic HP before reaching an IPF diagnosis [7]. The challenges faced in diagnosing HP are highlighted
by a recent multi-centre study showing the poor inter-multidisciplinary team agreement in diagnosing
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HP (weighted kappa = 0.29; interquartile range (IQR) 0.24–0.4), compared to a markedly better
agreement between different multidisciplinary teams (MDTs) in diagnosing IPF (weighted kappa = 0.71;
IQR 0.64–0.77) [8]. From a therapeutic management perspective, the distinction between IPF and
an inflammation-driven disorder such as fibrotic HP is crucial, since immunosuppressive therapy is
considered to be harmful in IPF [9], but may be appropriate in fibrotic HP. Conversely, anti-fibrotic
regimens have been licensed for IPF, but not for fibrotic HP.
In HP, the presence of fibrosis histologically or on chest computer tomography (CT) is associated
with a decreased survival. In view of this and of the diagnostic difficulties in separating fibrotic
HP from IPF or other interstitial lung diseases (ILDs) in a proportion of patients, this review article
focuses on fibrotic HP with particular attention to current knowledge on the diagnosis, management,
and prognosis of this form of the disease. In addition, steps in the diagnostic approach that may be
helpful in distinguishing fibrotic HP from IPF are discussed. For the purpose of this review we will
use the term fibrotic HP rather than chronic HP, as there can be patients with a chronic subacute form
without significant fibrosis visible on CT.
2. Diagnosis of Fibrotic HP
The diagnosis of fibrotic HP relies on the integration of: (a) non-specific symptoms, such
as dyspnea and cough, as well as fatigue and malaise, that develop in a specific environment,
(b) compatible chest CT scan features, (c) detection of serum antibodies against suspected antigens,
(d) lymphocytosis on bronchoalveolar lavage (BAL), and/or (e) identification of a granulomatous
bronchiolocentric interstitial pneumonitis on adequate lung biopsies. None of the above features is
specific for the diagnosis of HP in isolation. Although internationally-agreed guidelines are lacking,
a diagnosis of HP is based on variable combinations of the above features in the individual patient.
We will detail each of the features that can lead to a diagnosis of fibrotic HP below.
2.1. Exposures
A careful and thorough exposure history is key in the diagnostic approach of the individual
patient. Since the first description of farmer’s lung in the 60 s, the wide list of agents associated with the
development of HP has continued to expand, including fungal, bacterial, protozoal, and animal proteins,
as well as low-molecular-weight chemical compounds. However, the most common causes of HP are
exposure to avian antigens, or to fungi/actinomyces in the home or in the working environment [1].
The classic association with avian antigen exposure occurs in pigeon breeders [10,11], or in individuals
keeping parakeets/cockatiels as pets in their homes [12], although exposure can be more subtle, and
cases of HP related to birds visiting areas adjacent to the home [13], or even in feather pillows, duvets or
mattress covers have been described [14]. Avian antigens can remain in the house long after the removal
of the birds themselves, something that needs to be considered when counselling the patient [12,13,15].
Visible mould and known water damage for a number of reasons (e.g., floods, leaks) in the home
or the occupational environment have been associated with HP, as they are related to inhalation of
specific microbiologic agents [16]. In addition, questions about exposures to greenhouses, compost,
mushroom farming, and other food production methods where mould growth can occur should be
included in the patient’s detailed history [17–20]. More recently, hot tub lung and metalworking
fluid-related HP have been described [21–23]. Non-tuberculous mycobacteria have been identified
in patients exposed to indoor hot tubs and outdoor pools [21], and metal working fluids can be
contaminated by bacterial, mycobacterial, and fungal organisms [23]. Finally, specific chemicals used
in industry, such as isocyanates and anhydrides, should also be considered as causal antigens. A more
detailed list of HP antigens can be found in dedicated reviews [24]. An example of how an exposure
can be missed if not specifically considered, is the case of a patient attending the Royal Brompton ILD
clinic with clinical and radiological features consistent with fibrotic HP. The patient had been managed
for fibrotic HP for a few years, but it was only when he mentioned that his symptoms improved
when on holiday that a work exposure was queried. A bronchoalveolar lavage performed after he
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had returned to work post-holidays revealed marked lymphocytosis of 54%, suggestive of ongoing
exposure and inflammation, as well as mild neutrophilia (5.6%). A detailed occupational history
revealed exposure to metalworking fluids in an aircraft factory, confirmed by an inspection of his work
environment, and gradual symptomatic and functional improvement was noted since removing the
exposure and introducing immunosuppressive treatment.
The time interval between the onset of the exposure and the onset of disease is variable and
may range from months to decades [25]. Patients in whom the offending antigen is identified have
a better prognosis [15]. However, disease progression even after termination of the antigen exposure
often occurs. Furthermore, finding the inciting antigen is extremely difficult in fibrotic HP. In a series
of 85 consecutive cases, no antigen was identified in 25% [16], while in another series of 142 cases;
a responsible antigen was not detected in 53% of the patients [15]. These studies illustrate the challenges
faced and the importance of determining the relevant exposure, not just for the management of fibrotic
HP, but also in the evaluation of fibrotic lung diseases overall. A thorough exposure history looking for
exposures associated with HP, including attention to seemingly minor exposures is, thus, an essential
part of the evaluation of patients presenting with diffuse parenchymal lung disease.
2.2. High Resolution CT Findings
Chest CT evaluation forms a central component of the diagnostic work-up of a patient with fibrotic
lung disease. In subacute HP, ground-glass opacities that are considered to represent lymphocytic
alveolar inflammation and organizing pneumonia can be seen alongside poorly-defined centrilobular
nodules, which are thought to reflect cellular bronchiolitis [26–28].
In fibrotic HP, CT patterns including reticulation, traction bronchiectasis and volume loss, with
or without evidence of honeycombing, are all seen (Figure 1) [26,28]. Patients often demonstrate
an upper lobe predominant distribution of fibrosis, but diffuse and lower lobe predominant changes
have also been described. Furthermore, a faint bronchocentricity to the fibrosis can be observed at the
lung apices. Similarly, reticulation in fibrotic HP is considered to have a predominantly subpleural or
peri-bronchovascular distribution.
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Figure 1. Features suggestive of chronic hypersensitivity pneumonitis in different patients. (A) Spared 
pulmonary  lobules are visible within non‐fibrotic  lung bilaterally  (arrows); background  fibrosis  is 
evidenced  by  peripheral  reticulation  and  traction  bronchiectasis  (black  arrowheads).  (B,C)  A 
predilection  towards  bronchocentricity  of  the  fibrosis  in  the  upper  lobes  is  evident  on  axial 
(arrowheads) and coronal (arrows) images. (D) An upper and midzone predominance to the fibrosis, 
characterised by reticulation and traction bronchiectasis, is seen on a coronal CT. Incidentally, volume 
loss in the right lung is noticeable by slight tenting and elevation of the right hemidiaphragm (arrow). 
(E) A UIP pattern with honeycomb cysts is visible in the left midzone of the lung (arrowhead) in a 74‐
year‐old male ex‐smoker. A surgical biopsy performed a few years before this CT had demonstrated 
findings compatible with fibrotic hypersensitivity pneumonitis. 
In a study of 92 patients with fibrotic HP, ground glass opacification and reticulation were the 
most  prevalent  patterns  of  interstitial  disease  [27].  Interestingly,  microcystic  and  macrocystic 
honeycombing were described  in 32% and 13% patients,  respectively. The prevalence of  traction 
Figure 1. Features suggestive of chronic hypersensitivity pneumonitis in different patients.
(A) Spared pulmonary lobules are visible within non-fibrotic lung bilaterally (arrows); background
fibrosis is evidenced by peripheral reticulation and traction bronchiectasis (black arrowheads).
(B,C) A predilection towards bronchocentricity of the fibrosis in the upper lobes is evident on axial
(arrowhe ds) and coronal (arrows) images. (D) An upper and midzone predomina ce to the fibrosis,
characterised by reticulation and traction bro chiectasis, is seen on a coronal CT. Incident lly, volume
loss in the right lung is noticeable by slight tenting and elevation of the right hemidiaphragm (arrow).
(E) A UIP pattern with honeycomb cysts is visible in the left midzone of the lung (arrowhead)
in a 74-year-old male ex-smoker. A surgical biopsy performed a few years before this CT had
demonstrated findings compatible with fibrotic hypersensitivity pneumonitis.
In a study of 92 patients with fibrotic HP, ground glass opacification and reticulation were the most
prevalent patterns of interstitial disease [27]. Interestingly, microcystic and macrocystic honeycombing
were described in 32% and 13% patients, respectively. The prevalence of traction bronchiectasis
was greater within regions of ground glass opacification and reticular patterns than within areas
of honeycombing.
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Mosaic attenuation with patchy areas of air trapping in a lobular distribution, more obvious
on expiratory scans, is another important CT feature in HP. Lobular air trapping represents indirect
evidence of small airways obstruction. (Figure 1A) However, mosaic attenuation can also be observed
in other fibrotic lung diseases, including fibrotic sarcoidosis and connective tissue disease associated
interstitial lung disease, also related to small airways involvement. As a result, lobular air trapping,
which is often considered characteristic, may be a relatively non-specific finding. Interlobular septal
thickening can be particularly profuse in fibrotic HP, although this is also a feature of fibrotic sarcoidosis.
Consolidation is rare in HP and should raise the suspicion of alternative diagnoses such as fibrosing
organizing pneumonia or sarcoidosis. Finally, cysts have been reported in 13% of patients with
subacute HP but can also be seen in fibrotic HP [29]. The cysts are suspected to be a result of
bronchiolar obstruction secondary to peribronchiolar lymphocytic inflammation, similar to that seen
in lymphoid interstitial pneumonia.
Several of the chest CT features mentioned above, suggestive of a fibrotic HP diagnosis, have been
used to classify patients as having features inconsistent with a CT UIP pattern in the latest consensus
IPF diagnostic guidelines [7]. Specifically, the presence of extensive lobular air trapping, centrilobular
nodules, and the lack of a lower zone predominance to the fibrosis can be helpful in excluding IPF as
a working diagnosis (Table 1). Conversely, changes that are diffuse, but predominantly lower lobe in
distribution, and where areas of mosaic attenuation are not extensive (unilateral or involving less than
three lobes), make the diagnostic separation of fibrotic HP and IPF challenging. In a study of 66 patients
with fibrotic interstitial lung disease, a clear distinction between fibrotic HP and other fibrotic idiopathic
interstitial pneumonias on thin section CT was possible in only 53% of patients [30]. The diagnostic
difficulties were further highlighted by an international multicenter evaluation of 70 patients discussed
in a series of parallel multidisciplinary team meetings [8]. The inter-multidisciplinary meeting
discussion agreement among specialists on the diagnosis of hypersensitivity pneumonitis was the
lowest among ILD patterns (weighted kappa = 0.29 (0.24–0.40)), emphasizing the lack of confidence
even among ILD experts in the diagnosis of this entity.
Table 1. Similarities and differences in clinical, radiological and histopathological features between
fibrotic HP and idiopathic pulmonary fibrosis (IPF).
Features Fibrotic HP IPF
Demographics
Sex No difference More frequent in men
Smoking Protective Risk factor
Age No predilection More frequent > 55 years
Clinical symptoms/history
Clubbing Often Often
Squeaks Typical Absent
Bibasal crackles Frequent Frequent
Systemic disease features (fever, joint pains, fatigue) Often Absent
Exposure to antigens Frequent Rare
Positive precipitins Frequent Rare
Imaging (CT)
Distribution Upper lobe predominance Peripheral, predominantly basal
Mosaic attenuation Frequent Absent/Limited
Nodules Frequent Absent
Interlobular septal thickening Often Absent/Limited
Honeycombing Often Frequent (typical for UIP pattern)
Bronchocentricity Frequent Absent
Discrete cysts Often Absent
Consolidation Rare Absent
Bronchoalveolar lavage (BAL) Lymphocytosis > 25–30% Lymphocytosis < 20%
Histological
Fibroblast foci Often Frequent
Granulomas/giant cells/Schaumann bodies Frequent Rare
Organizing pneumonia Rare Rare
Honeycombing Often Frequent
Paraseptal subpleural distribution Often Frequent
Bronchocentricity Frequent Absent
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Chest CT imaging in fibrotic HP can provide useful information regarding patient prognosis.
Several studies have demonstrated that the presence and extent of fibrosis is predictive of mortality in
HP [27,31,32]. In a mixed study group of 69 patients with subacute and chronic HP, severe impairment
of pulmonary function and CT features of fibrosis were associated with a poor prognosis [31]. A study
of 92 patients with fibrotic HP concluded that an increased extent of fibrosis on CT conferred a worse
prognosis. The severity of traction bronchiectasis was found to be the strongest predictor of mortality,
and remained so after adjustment for disease severity. Traction bronchiectasis severity was also shown
to be superior to lung function tests in prognostic determination [27]. New quantitative imaging
techniques using automated computer-based CT (CALIPER) analysis have recently shown that the
extent of reticulation on CT is an independent predictor of mortality in fibrotic HP [32].
2.3. Serum Antibodies against Suspected Antigens
Positive precipitating antibodies to the offending antigen were considered in the clinical diagnosis
of HP by the HP Study Group in 2003 [1]. Positive precipitins were considered supportive of the
diagnosis in the appropriate clinical setting, since the presence of specific IgG antibodies to the
inducing antigen in isolation is evidence of sensitization but not necessarily of disease. In addition,
the significance of positive antibodies may differ according to exposure type. For example, healthy
farmers have been found to have precipitating antibodies to exposure antigens in 30% to 60% of
cases [33]. On the other hand, only 3% of healthy exposed budgerigar fanciers produce precipitating
antibodies [34]. In a significant proportion of patients, no serum precipitins are identified to support
the diagnosis of HP. Despite these limitations, the precipitin assay is a useful additional laboratory test
in the diagnostic assessment of HP, in particular to suggest a potential exposure that may have not
been recognized. Having said this, the newer ELISA-based assays are more sensitive, but less specific,
than the traditional precipitating antibody assays, and the finding of a positive result must always be
interpreted in the context of the individual patient’s exposures [24].
A natural challenge at the workplace or home, or a “provoked” inhalation challenge under
standardized conditions after a period of avoidance, has been used in a few studies to support the
diagnosis of HP and identify the specific antigen [35–38]. The lack of standardized antigens and
challenge techniques has restricted the widespread use of such techniques.
2.4. Bronchoalveolar Lavage (BAL)
BAL is overall a well-tolerated interventional diagnostic procedure. It is widely used as
a highly-sensitive diagnostic tool to detect alveolar inflammation in patients with interstitial lung
disease. BAL has established diagnostic value in the diagnosis of HP, sarcoidosis, infections,
and malignancy, which remain in the differential diagnosis of patients with idiopathic interstitial
pneumonias. HP is characterized by an increase in the total cell count with elevation in the percentage of
lymphocytes. The exact level of lymphocytes that differentiates HP from other disorders is not known,
but in published series an increase in lymphocytes >50% is highly indicative [5,39]. A CD4/CD8 ratio <1
has also been considered suggestive of the diagnosis [40]. However, CD4/CD8 ratio measurements
are no longer recommended, as the ratio may vary significantly according to exposure and disease
stage. In addition, a normal or elevated ratio does not exclude HP [41,42]. With regards to the cytology
cell differential count, it should be noted that acute episodes of exposure to relevant antigens may
be associated with an increase in the number of neutrophils, reverting back to the predominantly
lymphocytic profile after a few days [42]. On patient follow-up, the finding of a persistent BAL
lymphocytosis may indicate that complete antigen exposure elimination has not been achieved.
Although the 2002 ATS/ERS international consensus classification of idiopathic interstitial
pneumonias (IIPs) did not consider BAL analysis essential in the diagnostic workup of IPF [43],
this remains a key element in the diagnosis/exclusion of fibrotic HP. However, the alveolar
inflammation noted in patients with HP is less prominent when the disease is fibrotic [5,39]. Ohtani et al.
reported a mean lymphocyte count of 19% when a UIP pattern on CT was evident in patients with
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fibrotic HP [39], while another series reported a mean BAL lymphocytosis of 36% in patients with
a UIP pattern on CT, compared to 65% in those with a typical subacute HP pattern on CT [5]. There is
no consensus on the exact percentage of BAL lymphocytes threshold useful to differentiate fibrotic
HP from IPF. In a study of 74 patients with suspected IPF on chest CT, a BAL lymphocytosis cut-off
threshold of 30% managed to differentiate 6/74 (8%) of patients from IPF, results that were later on
confirmed on surgical biopsies and/or disease behaviour [44]. The mean lymphocyte count in BAL of
patients with IPF is 11% and the vast majority of IPF patients have less than 20% lymphocytes [45].
These findings would suggest that fibrotic HP is highly likely in a patient with evidence of fibrotic
lung disease and an elevated BAL lymphocyte count even if the HRCT is suggestive of a UIP pattern,
although further studies are needed. Surgical lung biopsies may be efficacious in this setting but
other important factors will also contribute to the final diagnosis. The study by Morell et al. reporting
that among 46 patients with a diagnosis of IPF, a subsequent diagnosis of fibrotic HP was made in
20 patients, would imply that BAL should be performed routinely in all patients with fibrotic interstitial
lung disease [46].
2.5. Histopathology
Although in a large proportion of cases, the diagnosis of HP can be reached through the criteria
outlined above, a surgical lung biopsy is required in cases with low to moderate pretest likelihood of
the disease diagnosis. This occurs mostly in patients with overlap of subacute/fibrotic HP findings
on CT.
The primary histopathological features considered characteristic of subacute HP include the triad
of cellular bronchiolitis, lymphoplasmacytic interstitial infiltrates, and non-necrotizing granulomas
(Figure 2) [47]. The inflammation is composed mainly of lymphocytes in a bronchiolocentric
distribution. Proliferative bronchiolitis obliterans has been described in patients with farmer’s lung,
while constrictive bronchiolitis has been reported in pigeon breeder’s disease [48,49]. The granulomas
are small in size and not as well-formed as those seen in sarcoidosis. Multinucleated giant cells may
be present as constituents of granulomas and/or also be present singly, not infrequently containing
cholesterol clefts. It should be noted that granulomatous features may be absent in almost one third of
surgical lung biopsies from patients with fibrotic HP [50]. Most granulomas are identifiable on routine
staining, although cathepsin K, a protease expressed in activated macrophages, may be of additional
value. However, it is not specific for HP granulomas [51]. Finally, occasional areas of organizing
pneumonia with Masson bodies are often seen in subacute damage, while peribronchial lymphoid
hyperplasia is frequently evident [50].
The histopathological patterns observed in fibrotic HP are characterized by variable degrees of
fibrotic changes and are considered similar to those of NSIP or UIP in up to 88% of cases (Figure 3) [52–54].
Detecting fibrotic changes on biopsy is crucial as the presence of fibrosis is an independent predictor of
morbidity and mortality in HP. Histopathologic patterns of fibrotic NSIP and UIP pattern in 119 patients
were significantly correlated with a worse transplant-free survival time [55], while the presence of
fibroblast foci on biopsies, regardless of the underlying histopathologic pattern, was found to be
an independent predictor of survival in HP patients in two studies [55,56]. Evidence of organizing
pneumonia and/or cellular NSIP pattern in surgical lung biopsies of patients with chronic bird
fancier’s disease was most often noted in acute episodes of the disease and resulted in a more
favourable outcome compared to patients with fibrotic NSIP and/or UIP pattern [39]. In one study,
the median survival of fibrotic HP varied between 5–9 years depending on the identification of the
inciting antigen [15], a survival that is considerably lower than the one reported for non-fibrotic cases.
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Figure 2. (A) A case of hypersensitivity pneumonitis shows peribronchiolar chronic inflammation of
varying intensity around bronchovascular bundles. (B) A single, small, poorly-formed granuloma is
found within the interstitium
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Figures 3. (A–C) A case of chronic hypersensitivity pneumonitis shows (A) areas of patchy subpleural 
dense fibrosis and (B) focal honeycomb change, typical of a pattern of usual interstitial pneumonia. 
(C) Rare peribronchiolar granulomas are also seen. 
2.5.1. Distinguishing Fibrotic HP Associated with a UIP/Fibrotic NSIP Pattern from UIP/IPF 
In patients with a CT consistent with  fibrotic NSIP/UIP pattern,  in whom HP  is suspected, a 
biopsy can be helpful in differentiating fibrotic HP from IPF. The bronchiolocentric distribution of 
the fibrotic changes and the presence of signs of granulomatous inflammation, including giant cells, 
or granulomas, are supportive of the diagnosis of fibrotic HP. However, there are limitations. None 
of the features above are specific for HP, as each in isolation can also be found in IPF. On the other 
hand, the granulomatous inflammation becomes less prominent as the fibrotic disease progresses. In 
one study, 8% of cases were  indistinguishable  from UIP/IPF on histopathological analysis  [57].  It 
remains  unclear  whether  fibrotic  HP  with  a  UIP  pattern  on  biopsy  behaves  differently  from 
idiopathic UIP/IPF [58]. In a study of 16 patients with fibrotic HP and a UIP pattern on biopsy, there 
were  no  lymphocytosis  on  BAL  and  the  distribution  of  fibrosis  on  chest  CT  scans  was  less 
predominant in 50% of patients while no zonal predominance was identified in 37.5% of patients [58]. 
The extent of fibrosis was significantly correlated with an increased risk for mortality (hazard ratio, 
2.36;  95%  CI,  1.02–5.48;  p  =  0.04)  and  there  was  a  trend  for  an  inverse  association  with  acute 
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dense fibrosis and (B) focal honeycomb change, typical of a pattern of usual interstitial pneumonia.
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2.5.1. Distinguishing Fibrotic HP Associated with a UIP/Fibrotic NSIP Pattern from UIP/IPF
In patients with a CT consistent with fibrotic NSIP/UIP pattern, in whom HP is suspected,
a biopsy can be helpful in differentiating fibrotic HP from IPF. The bronchiolocentric distribution of
the fibrotic changes and the presence of signs of granulomatous inflammation, including giant cells,
or granulomas, are supportive of the diagnosis of fibrotic HP. However, there are limitations. None
of the features above are specific for HP, as each in isolation can also be found in IPF. On the other
hand, the granulomatous inflammation becomes less prominent as the fibrotic disease progresses.
In one study, 8% of cases were indistinguishable from UIP/IPF on histopathological analysis [57].
It remains unclear whether fibrotic HP with a UIP pattern on biopsy behaves differently from idiopathic
UIP/IPF [58]. In a study of 16 patients with fibrotic HP and a UIP pattern on biopsy, there were no
lymphocytosis on BAL and the distribution of fibrosis on chest CT scans was less predominant in 50%
of patients while no zonal predominance was identified in 37.5% of patients [58]. The extent of fibrosis
was significantly correlated with an increased risk for mortality (hazard ratio, 2.36; 95% CI, 1.02–5.48;
p = 0.04) and there was a trend for an inverse association with acute exacerbation-free interval.
2.5.2. Cryobiopsy
In view of the risks of a surgical biopsy, alternative ways of obtaining lung tissue for histology
have been developed. Conventional transbronchial biopsies are associated with a low diagnostic
yield, related to the small sample size, coupled with the patchy nature of interstitial involvement.
Increasingly, transbronchial cryobiopsies are being used in a number of ILD centres, as the technique
allows for larger sample size, fewer crush artefacts and, therefore, higher diagnostic yields compared
to the conventional transbronchial biopsies. A significantly lower mortality rate in expert centres
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compared to a surgical lung biopsy (<0.5% vs. 2–4%) was recently reported [59]. In another recent study
comparing the diagnostic accuracy and safety profile of transbronchial cryobiopsy and video-assisted
thoracoscopic (VATS) lung biopsy, Iftikhar et al. showed that the pooled diagnostic yield was
comparatively lower than VATS lung biopsy, although not markedly so (83.7% vs. 92.7%), while
the incidence of significant bleeding and pneumothorax post the transbronchial biopsy was considered
acceptable (4.9% and 9.5%, respectively) [60]. However, the specific diagnostic yield of a cryobiopsy
in relation to distinguishing UIP associated with HP versus UIP/IPF remains to be established.
3. Management of Fibrotic HP
Management decisions in HP can involve modification of both the environment (antigen avoidance)
and the host immune response. Avoidance of antigen exposure is often effective in cases of acute and
sub-acute HP, but is usually insufficient in isolation in fibrotic HP. Fibrotic HP is widely considered
to be inflammation driven and, thus, immunosuppression tends to be used, especially in cases with
disease progression. The underlying assumption is that the disease regression seen with corticosteroids
in cases of acute and sub-acute HP can be extrapolated to the prevention or reduction of progression
in chronic HP. However, no controlled data exist to confirm this view and there is no consensus on
an optimal regimen, including the level and duration of corticosteroid and/or immunosuppressive
therapy. Furthermore, given the frequent difficulty in distinguishing between chronic HP and IPF, there
is a concern that high dose corticosteroids/immunosuppression may have deleterious effects in some
patients with a provisional diagnosis of fibrotic HP who do, in reality, have IPF [9].
In view of the significant side effects of long term high dose corticosteroid treatment,
mycophenolate mofetil (MMF) and azathioprine (AZA) are frequently used as steroid-sparing agents.
Treatment with MMF or AZA was associated with a statistically significant improvement in gas transfer
values after one year of treatment in a recent study comparing the two regimens in patients with
fibrotic HP [61]. More intensive immunosuppression has been used in cases of rapidly progressive
non-IPF interstitial lung disease. One case with admixed subacute/fibrotic HP experienced a dramatic
improvement in symptoms and lung function post Rituximab, despite failure to respond to intravenous
cyclophosphamide [62]. In the study by Keir et al., six patients with fibrotic HP whose lung function
tests had declined despite conventional immunosuppressive therapy were treated with rituximab [63].
Following rituximab, pulmonary function tests stabilized or improved in three patients out of six and
continued to deteriorate in the other three patients, all of whom died within four months of treatment.
Prospective randomized trials are needed to validate the effectiveness of the available
immunosuppressive regimens in patients with fibrotic HP. On the other hand, it is clear that some
patients with fibrotic HP have a longitudinal behaviour akin to IPF, with relentless ongoing progression
and early mortality despite immunosuppression. At the moment, there is no means of determining
which patients with fibrotic HP will follow an IPF-like course. High throughput studies investigating
genomic, epigenomic, and proteomic biomarkers in fibrotic HP and other fibrotic ILDs are needed to
improve diagnostic and prognostic accuracy, in combination with current CT and histologic criteria.
The use of anti-fibrotic drugs such as pirfenidone and nintedanib, proven to slow down functional
decline in IPF, has been suggested as an option for patients with progressive fibrotic HP and no
documented response to corticosteroids and/or immunosuppressants [64]. A number of randomized
placebo-controlled trials are currently recruiting in non-IPF progressive fibrosis patient groups, including
a trial evaluating the effects of pirfenidone as an add-on drug to background immunosuppressive
treatment in patients with fibrotic HP (clinical trial gov. number: NCT02496182) [65], and a study
(clinical trial gov. number: NCT02999178) is evaluating the effects of nintedanib compared to placebo in
a wider group of patients with non-IPF progressive fibrotic lung disease, including fibrotic HP [66].
4. Conclusions
The development and the clinical patterns of HP are influenced by a number of factors, including:
(a) the nature/amount of inhaled antigens, (b) the intensity and frequency of exposure, and (c) the host
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immune/fibrotic response, in turn likely influenced by a predisposing genetic background. An accurate
diagnosis of fibrotic HP is essential, as fibrotic HP requires a distinct management from IPF and is
largely linked with a better disease outcome. However, a proportion of patients with fibrotic HP have
an IPF-like disease progression and survival, and may benefit from anti-fibrotic drugs, to be tested
in appropriately powered clinical trials. Further knowledge is needed on the molecular pathways
underlying progressive fibrosis in fibrotic HP and the different phenotypes of the disease, so as to
allow: (a) early detection and intervention to prevent disease progression to irreversible fibrosis;
(b) improved targeting of available immunosuppressive and/or anti-fibrotic agents to the appropriate
patient subgroups; and (c) identification of novel targets for more effective treatment.
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